| http://www.w3.org/ns/prov#value | - ST. PAUL, MN--(Marketwire - June 14, 2011) - EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced that updated weight loss data from clinical studies of the Company's VBLOC?? vagal blocking therapy delivered via the Maestro?? Rechargeable (RC) System will be presented at the 28th Ann
|
